Avacta submits documentation for rapid antigen test to MHRA

Avacta Group has announced that the Declaration of Conformity for CE mark of its AffiDX SARS-CoV-2 antigen rapid test for professional use has been submitted to the MHRA through its partner Mologic.

Show CommentsClose Comments

Leave a comment

%d bloggers like this: